192 related articles for article (PubMed ID: 37235690)
21. Corticosteroids as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplant recipients with calcineurin inhibitor intolerance.
Puckrin R; Kwan ACF; Blosser N; Leyshon C; Duggan P; Daly A; Zepeda V; Stewart D; Chaudhry A; Storek J; Jamani K
Cytotherapy; 2023 Oct; 25(10):1101-1106. PubMed ID: 37306643
[TBL] [Abstract][Full Text] [Related]
22. Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial.
Qian L; Liu M; Shen J; Cen J; Zhao D
Front Immunol; 2020; 11():598359. PubMed ID: 33324415
[TBL] [Abstract][Full Text] [Related]
23. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.
Pratta M; Paczesny S; Socie G; Barkey N; Liu H; Owens S; Arbushites MC; Schroeder MA; Howell MD
Br J Haematol; 2022 Aug; 198(4):729-739. PubMed ID: 35689489
[TBL] [Abstract][Full Text] [Related]
24. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation.
Quellmann S; Schwarzer G; Hübel K; Greb A; Engert A; Bohlius J
Cochrane Database Syst Rev; 2008 Jul; (3):CD004885. PubMed ID: 18646116
[TBL] [Abstract][Full Text] [Related]
25. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.
McCaul KG; Nevill TJ; Barnett MJ; Toze CL; Currie CJ; Sutherland HJ; Conneally EA; Shepherd JD; Nantel SH; Hogge DE; Klingemann HG
J Hematother Stem Cell Res; 2000 Jun; 9(3):367-74. PubMed ID: 10894358
[TBL] [Abstract][Full Text] [Related]
26. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease.
Rodriguez-Otero P; Porcher R; Peffault de Latour R; Contreras M; Bouhnik Y; Xhaard A; Andreoli A; Ribaud P; Kapel N; Janin A; Socié G; Robin M
Blood; 2012 Jun; 119(24):5909-17. PubMed ID: 22555971
[TBL] [Abstract][Full Text] [Related]
27. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease.
Ibrahimova A; Davies SM; Lane A; Jordan MB; Lake K; Litts B; Chaturvedi V; Owsley E; Myers KC; Nelson AS; Mehta PA; Marsh RA; Khandelwal P
Pediatr Blood Cancer; 2021 Aug; 68(8):e28968. PubMed ID: 33861521
[TBL] [Abstract][Full Text] [Related]
28. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
Mohty M; Holler E; Jagasia M; Jenq R; Malard F; Martin P; Socié G; Zeiser R
Blood; 2020 Oct; 136(17):1903-1906. PubMed ID: 32756949
[TBL] [Abstract][Full Text] [Related]
29. Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
Etra A; Capellini A; Alousi A; Al Malki MM; Choe H; DeFilipp Z; Hogan WJ; Kitko CL; Ayuk F; Baez J; Gandhi I; Kasikis S; Gleich S; Hexner E; Hoepting M; Kapoor U; Kowalyk S; Kwon D; Langston A; Mielcarek M; Morales G; Özbek U; Qayed M; Reshef R; Rösler W; Spyrou N; Young R; Chen YB; Ferrara JLM; Levine JE
Blood; 2023 Feb; 141(5):481-489. PubMed ID: 36095841
[TBL] [Abstract][Full Text] [Related]
30. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
31. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.
Ferrara JL; Harris AC; Greenson JK; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Huber E; Landfried K; Akashi K; Vander Lugt M; Reddy P; Chin A; Zhang Q; Hanash S; Paczesny S
Blood; 2011 Dec; 118(25):6702-8. PubMed ID: 21979939
[TBL] [Abstract][Full Text] [Related]
32. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
De Togni E; Cole O; Abboud R
Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
[TBL] [Abstract][Full Text] [Related]
33. Prospective external validation of biomarkers to predict acute graft-versus-host disease severity.
Robin M; Porcher R; Michonneau D; Taurines L; de Fontbrune FS; Xhaard A; Oriano B; Sutra Del Galy A; Peffault de Latour R; Socié G; Schlageter MH
Blood Adv; 2022 Aug; 6(16):4763-4772. PubMed ID: 35667096
[TBL] [Abstract][Full Text] [Related]
34. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
[TBL] [Abstract][Full Text] [Related]
35. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.
Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA
Front Immunol; 2020; 11():668. PubMed ID: 32431694
[TBL] [Abstract][Full Text] [Related]
36. Graft-versus-host disease treatment: predictors of survival.
Levine JE; Logan B; Wu J; Alousi AM; Ho V; Bolaños-Meade J; Weisdorf D;
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1693-9. PubMed ID: 20541024
[TBL] [Abstract][Full Text] [Related]
37. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
[TBL] [Abstract][Full Text] [Related]
38. Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
Hotta M; Satake A; Yoshimura H; Fujita S; Katayama Y; Ota S; Hanamoto H; Oyake T; Ito S; Okada M; Nakanishi T; Ito T; Ishii K; Nomura S
Transplant Cell Ther; 2021 Aug; 27(8):660.e1-660.e8. PubMed ID: 33989832
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of intractable gastrointestinal tract graft-vs-host disease with oral beclomethasone dipropionate in pediatric and young adult patients: Case reports.
Akahane K; Watanabe A; Somazu S; Harama D; Shinohara T; Kasai S; Oshiro H; Goi K; Hasuda N; Ozawa C; Sugita K; Inukai T
Medicine (Baltimore); 2022 Mar; 101(11):. PubMed ID: 35356922
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.
Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Borjas-Almaguer OD; González-Llano O; Jaime-Pérez JC; Solano-Genesta M; Gómez-Guijosa M; Mancias-Guerra C; Tarin L; Gómez-Almaguer D
Haematologica; 2012 May; 97(5):717-22. PubMed ID: 22133770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
